Movatec (Meloxicam)

Meloxicam selectively blocks the cyclooxygenase‑2 (COX‑2) enzyme, which is responsible for producing prostaglandins that mediate inflammation, pain, and fever. By lowering prostaglandin synthesis, meloxicam diminishes the inflammatory response and provides analgesic effects while sparing COX‑1 activity that protects the stomach lining.

The appropriate dose of Movatec is determined by the prescribing healthcare professional based on the patient’s condition, age, renal and hepatic function, and response to therapy. Dosage adjustments are individualized, and patients should follow the prescriber’s instructions without self‑adjusting the amount.

The safety of meloxicam in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Movatec, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Compared with non‑selective NSAIDs, meloxicam offers a higher degree of COX‑2 selectivity, which may lower the risk of gastrointestinal irritation while still providing effective anti‑inflammatory and analgesic action. However, cardiovascular and renal safety considerations remain similar to other NSAIDs, and choice of therapy should be individualized.

Movatec should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture, heat, and direct sunlight. Do not store in a bathroom or near a kitchen sink where humidity is high.

Movatec is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with food may reduce stomach upset. Patients should swallow the tablet whole and not crush or chew it unless directed by a healthcare professional.

Serious risks include gastrointestinal ulceration or bleeding, cardiovascular events such as heart attack or stroke, severe liver injury, and hypersensitivity reactions like anaphylaxis or Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience severe abdominal pain, black stools, chest pain, shortness of breath, or skin rash.

Movatec is contraindicated in patients with known hypersensitivity to meloxicam or other NSAIDs, those with active gastrointestinal bleeding or ulceration, and individuals with severe renal or hepatic impairment. Caution is also advised for patients with a history of cardiovascular disease, uncontrolled hypertension, or asthma triggered by NSAIDs.